Moderate-and long-term follow up of chronic granulomatous disease and efficacy of preventive drugs

HUI Xiao-ying,SUN Jin-qiao,GAO Wei-yin,YING Wen-jing,LIU Dan-ru,YU Ye-hang,WANG Xiao-chuan

DOI: https://doi.org/10.3969/j.issn.1673-5501.2012.05.001

2012-01-01

Abstract:Objective To describe the clinical features of pediatric chronic granulomatous disease (CGD) and incidence of infection after treatment program (combine rhIFN-γ and TMP-SMX). Methods The follow-up study of clinical features, including the site of infection, the pathogen of infection, noninfectious inflammatory response and drug treatment, etc., was performed in CGD patients diagnosed in Children′s Hospital of Fudan University from January 2004 to December 2011. The incidence of infection calculated as per patient-year was compared between patients who received combination treatment program or separated TMP-SMX treatment. The clinical efficacy and safety of rhIFN-γ treatment were analyzed. Results A total of 29 cases were recruited into the study. The mean age of onset and diagnosis was 2.5 months and 2.4 years respectively. Mean duration of per follow-up patient was 2.9 years. ① The incidence of all infections, severe infections and non-severe infections was 1.8, 0.48 and 0.80 per patient-year. Lung infection and lymphadenitis were the most frequent manifestations both prior to diagnosis (49 and 26) and during follow-up (26 and 37). Mycobacteria species was the leading cause of infection (34/61) and death (3/4) in our cohort. ② Combined treatment program was used in 21 cases while separated TMP-SMX treatment was performed in 8 cases because of drug adverse reaction or self-withdrawal. After combined treatment, the incidence of total and severe infection was significantly lower than that prior to treatment(total infection: 1.986 vs 1.098, P=0.002; severe infection:1.290 vs 0.452, P=0.001), the most remarkable to the lung (0.758 vs 0.275, P=0.004), the incidence of infection did not significantly differ from separated TMP-SMX treatment. The incidence of total and non-severe infection in combined treatment program was significant lower than that in separated TMP-SMX treatment (total infection: 1.098 vs 1.823, P=0.015; non-serious infection: 0.646 vs 1.248, P=0.047), serious infection had no significant difference (0.452 vs 0.576, P=0.254). ③ 14/29(48.3%)cases reported an adverse event after the use of rhIFN-γ, the commonest was fever (12/29). There was no life-threatening rhIFN-γ-related adverse events. Conclusions Combined treatment program significantly reduced the incidence of infection. The use of rhIFN-γ in patients with CGD appeared to be effective and safe. Mycobacteria species was the first cause of infection and death in our cohort.